Drugs Influencing Immune Function

Drugs influencing immune function are pharmaceutical agents designed to modulate, enhance, or suppress the body’s immune response. These include immunosuppressants (e.g., corticosteroids, cyclosporine), immunostimulants (e.g., interferons, vaccines), and biologic response modifiers (e.g., monoclonal antibodies like infliximab). They are commonly used in treating autoimmune diseases, preventing organ transplant rejection, managing allergies, and supporting cancer immunotherapy.

Immunosuppressive drugs work by inhibiting or reducing the activity of the immune system to prevent it from attacking healthy tissues or transplanted organs. Mechanisms vary by drug class: calcineurin inhibitors (like tacrolimus) block T-cell activation, corticosteroids reduce inflammation and immune cell proliferation, and antimetabolites (such as mycophenolate mofetil) interfere with DNA synthesis in immune cells. These medications require careful monitoring due to increased infection and malignancy risks.

Immune-modulating drugs are used to treat a wide range of conditions, including autoimmune disorders (e.g., rheumatoid arthritis, lupus, multiple sclerosis), inflammatory diseases (e.g., Crohn’s disease, psoriasis), organ transplant rejection, certain cancers (via immunotherapy), and primary or secondary immunodeficiencies. The choice of drug depends on the specific immune pathway involved and the clinical goals—whether suppression, stimulation, or targeted modulation is needed.

Common side effects of immune-affecting drugs include increased susceptibility to infections, fatigue, gastrointestinal disturbances, and elevated risk of certain cancers with long-term immunosuppression. Biologics may cause infusion reactions or allergic responses. Corticosteroids can lead to weight gain, osteoporosis, and glucose intolerance. Patients on these therapies typically require regular blood tests and clinical monitoring to manage risks and maintain therapeutic efficacy.

Selecting the appropriate immune-modulating therapy involves evaluating the patient’s diagnosis, disease severity, comorbidities, previous treatment responses, and potential drug interactions. Guidelines from organizations like the FDA, EMA, or professional societies (e.g., ACR for rheumatology) provide evidence-based recommendations. Factors such as route of administration, dosing frequency, cost, and access to biosimilars also influence decision-making. Close collaboration between specialists ensures safe and effective use of these potent medications.